

A Novel Inhibitor of IDO1

Drug Name	***0157
Description	Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting enzyme that catalyzes the conversion of tryptophan into kynurenine. The depletion of tryptophan and the increase in kynurenine have important immunosuppressive functions in cancers. A novel small molecule inhibitor of IDO1 is in preclinical development and may be a therapeutic opportunity in cancer immunotherapy beyond checkpoint blockade.
Target	IDO1
Drug Modality	Small Molecule
Indication	Cancer
Product Category	Cancer Immunotherapy
Mechanism of Action	Inhibiting IDO1 and decreasing kynurenine levels to reverse immunosuppression
Status	Preclinical
Patent	Granted

More Detail Available Upon Request

We look forward to hearing from you.